Effect of Steady-State Faldaprevir on the Pharmacokinetics of Steady-State Methadone and Buprenorphine-Naloxone in Subjects Receiving Stable Addiction Management Therapy
David Joseph(Boehringer Ingelheim (United States)), Fenglei Huang(Boehringer Ingelheim (United States)), Abidemi Adeniji(Boehringer Ingelheim (United States)), Michael J. Schobelock(Boehringer Ingelheim (United States)), R. Riesenberg, Bradley Vince(Altasciences Clinical Research Vince & Associates), Mabrouk Elgadi(Boehringer Ingelheim (Canada)), Lynn R. Webster(Adherent Technologies (United States))
Cited by 7
Related Papers
Predicting Aberrant Behaviors in Opioid-Treated Patients: Preliminary Validation of the Opioid Risk Tool
|Pain Medicine|2005|1.1k
Risk Factors for Opioid-Use Disorder and Overdose
|Anesthesia & Analgesia|2017|504
Naloxegol for Opioid-Induced Constipation in Patients with Noncancer Pain
|New England Journal of Medicine|2014|331
Sleep-Disordered Breathing and Chronic Opioid Therapy
|Pain Medicine|2007|309
A Randomized, Double-Blind, Placebo-Controlled Study of Intrathecal Ziconotide in Adults with Severe Chronic Pain
|Journal of Pain and Symptom Management|2006|304